Drugs / MK-8558
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03859739 | Apr 2019 → May 2020 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03859739 ↗ |
| Route | Oral | “Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.” NCT03859739 ↗ |